GENEVA--(Marketwire - April 28, 2010) -
Addex Pharmaceuticals / Addex to Host R&D Day on May 11 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 28 April 2010 - Allosteric modulation company Addex Pharmaceuticals (SIX: ADXN) invites investors, analysts and media to attend our annual R&D day on Tuesday, May 11, from 11:00am to 3:30pm CET in our headquarters or via an interactive webcast hosted on our website. Addex will disclose new details about the status of our co-lead clinical stage products:
* ADX48621 is scheduled to start in 2010 Phase II testing in patients with Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Phase IIa testing in patients with dystonia. ADX48621 is an mGluR5 negative allosteric modulator (NAM) wholly owned by Addex. Inhibition of mGluR5 is a clinically validated mechanism in PD-LID.
* ADX71149: Subject to the successful completion of the ongoing Phase I
program and regulatory approvals, ADX71149 is expected to start Phase
IIa
testing for schizophrenia and anxiety in 2010. ADX71149 is an mGluR2
positive allosteric modulator (PAM) being developed by our partner
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Activation of mGluR2 is a
clinically validated mechanism in both schizophrenia and anxiety.
Addex will disclose new preclinical data from selected discovery programs:
* Our collaboration with Merck & Co., Inc. to develop mGluR4 PAM for treatment of Parkinson's disease and other indications
* Wholly owned projects to develop:
* orally available small molecule PAM for the GLP-1 receptor - Type II diabetes * orally available small molecule NAM for the IL-1 receptor 1 - Gout and Type II diabetes
Addex will describe proprietary tools enabling industrialization of
allosteric
modulator drug discovery and development.
Interested parties are encouraged to attend in person. A complete program will be made available on our website prior to the event. The Addex R&D Day presentations, related question and answer sessions and supporting documents will be webcast live, recorded and made available via www.addexpharma.com.
RVSP via
investor.relations@addexpharma.com
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric modulators for human health and is focused on validated therapeutic targets for diseases of the central nervous system, metabolic disorders and inflammation. Subject to the completion of Phase I testing and regulatory approvals, Phase II clinical trials are expected to start in 2010 in four indications for two lead products: ADX48621, an mGluR5 negative allosteric modulator (NAM), in dystonia and Parkinson's disease levodopa- induced dyskinesia (PD-LID); and ADX71149, an mGluR2 positive allosteric modulator (PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-B receptor PAM with potential for chronic pain, is scheduled to enter Phase I testing around the end of 2010. In addition, Merck & Co., Inc. has licensed rights to two preclinical products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia. Additional preclinical discovery stage programs include: mGluR2 NAM, GLP1R PAM, IL1R1 NAM and TNFR1 NAM. Roche Venture Fund and SR-One, corporate venture arm of GlaxoSmithKline, are investors in Addex.
Disclaimer: The foregoing release may contain forward-looking statements
that
can be identified by terminology such as "not approvable",
"continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could",
or similar expressions, or by express or implied discussions regarding
Addex
Pharmaceuticals Ltd, its business, the potential approval of its
products by
regulatory authorities, or regarding potential future revenues from
such
products. Such forward-looking statements reflect the current views of
Addex
Pharmaceuticals Ltd regarding future events, future economic
performance or
prospects, and, by their very nature, involve inherent risks and
uncertainties,
both general and specific, whether known or unknown, and/or any other
factor
that may materially differ from the plans, objectives, expectations,
estimates
and intentions expressed or implied in such forward-looking statements.
Such may
in particular cause actual results with allosteric modulators of mGluR2,
mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different
from any
future results, performance or achievements expressed or implied by
such
statements. There can be no guarantee that allosteric modulators of
mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or
by any
regulatory authority. Nor can there be any guarantee that allosteric
modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will
achieve any
particular levels of revenue (if any) in the future. In particular,
management's
expectations regarding allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7
or other therapeutic targets could be affected by, among other
things,
unexpected actions by our partners, unexpected regulatory actions or
delays or
government regulation generally; unexpected clinical trial results,
including
unexpected new clinical data and unexpected additional analysis of
existing
clinical data; competition in general; government, industry and general
public
pricing pressures; the company's ability to obtain or maintain patent or
other
proprietary intellectual property protection. Should one or more of these
risks
or uncertainties materialize, or should underlying assumptions prove
incorrect,
actual results may vary materially from those anticipated, believed,
estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in
this
press release as of this date and does not undertake any obligation to
update
any forward-looking statements contained in this press release as a
result of
new information, future events or otherwise, except as may be
required by
applicable laws.
[HUG#1409209]
--- End of Message ---
Addex Pharmaceuticals 12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
ISIN: CH0029850754;
PDF (English): http://hugin.info/138017/R/1409209/361855.pdf
